Featured Content

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

A large, long-term study found a 97% event-free survival rate at 18 months.

Triclosan and Cancer Risk: Is There a Link?

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Is Genomic Medicine Failing Minority Patients?

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision ...

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

New findings bolster the case for the predictive utility of ARID1A mutations.

More Features>>>

Chronic Myeloid Leukemia Resources

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs